Shares of Hims & Hers Health, Inc. (NYSE: HIMS) surged by 30% on April 29, 2025, following the announcement of a significant long-term collaboration with Novo Nordisk (NYSE: NVO) aimed at enhancing obesity care in the United States. This partnership is set to make obesity treatments more accessible and affordable through the Hims & Hers platform, which is known for its telehealth services.
The collaboration introduces a bundled offering that includes Novo Nordisk’s popular weight loss drug, Wegovy, along with a Hims & Hers membership. This membership provides users with 24/7 care, clinical support, and nutrition guidance, all starting at a price of $599 per month. The service is now available on the Hims & Hers platform, marking a significant step in a broader roadmap to improve obesity care outcomes.
Andrew Dudum, CEO and founder of Hims & Hers, expressed enthusiasm about the partnership, stating, "We are excited to partner with Novo Nordisk to bring innovative healthcare solutions to patients. Our shared commitment to making healthcare more accessible aligns perfectly with this initiative."
Dave Moore, Executive Vice President of Novo Nordisk Inc., also highlighted the importance of this collaboration, emphasizing the goal of improving chronic disease outcomes in a more affordable manner. He stated, "We are seeing more and more patients receiving access to care for obesity through telehealth, and we wanted to make sure that we could be there and provide real Wegovy at the same place that they are receiving care."
The stock's positive movement reflects investor optimism surrounding Hims & Hers' potential to broaden its service offerings and tap into the growing demand for accessible healthcare solutions. In premarket trading, shares of Hims & Hers climbed approximately 36%, showcasing the market's positive reception to the news.
This partnership represents a strategic shift for both companies, as they aim to leverage Novo Nordisk’s expertise in clinical medicine alongside Hims & Hers’ digital health platform to scale access to quality care. The initiative expands on Hims & Hers’ existing weight loss solutions, which already offer a comprehensive approach to health management that includes a variety of medications, kits, and care plans.
The collaboration comes at a time when Novo Nordisk is actively expanding its reach in the obesity treatment market. Recently, the company announced its partnership with Hims & Hers, Ro, and LifeMD to sell branded versions of Wegovy through telehealth platforms, making the drug more accessible to cash-paying customers. This move follows a U.S. judge's decision on April 24, 2025, to reject a bid by compounding pharmacies to continue making copies of Novo’s popular diabetes and weight-loss drugs, Ozempic and Wegovy, amid ongoing legal challenges.
As part of this initiative, Novo Nordisk had previously launched the NovoCare Pharmacy program in March 2025, which allows self-paying patients to access Wegovy at a reduced cost of $499. The recent collaboration with Hims & Hers will further enhance these offerings by bundling the membership and access to all Wegovy doses, starting at $599 per month.
Moore added, "This should also be a very clear message that we have full supply of Wegovy. We want everyone to know that all doses are available." The availability of Wegovy through telehealth platforms is a significant development, especially as demand for obesity treatments continues to rise.
Hims & Hers’ stock has seen considerable fluctuations in response to market dynamics, but this latest partnership marks one of its best trading days ever. The company is poised to solidify its position in the telehealth market, particularly in the realm of obesity care, which has become increasingly important as more individuals seek effective weight management solutions.
In addition to the partnership with Novo Nordisk, Hims & Hers continues to offer personalized compounded versions of semaglutide on its platform, providing patients with a range of options for weight management. Dudum stated, "Adding Novo Nordisk's FDA-approved treatments at the best available cash price will help more patients nationwide get the obesity care they need to achieve their goals, particularly those without insurance coverage."
This collaboration is not just about improving access to medication; it reflects a broader trend in healthcare toward integrating technology with traditional medical practices to enhance patient care. As telehealth continues to evolve, partnerships like this one between Hims & Hers and Novo Nordisk may pave the way for more innovative solutions in the healthcare landscape.
As the obesity epidemic continues to affect millions of Americans, initiatives like this partnership are crucial in addressing the urgent need for effective treatment options. The collaboration between Hims & Hers and Novo Nordisk is expected to play a significant role in shaping the future of obesity care, making it more accessible and affordable for those in need.
In summary, the partnership between Hims & Hers and Novo Nordisk represents a significant step forward in the fight against obesity, combining the strengths of both companies to provide comprehensive care solutions. With the launch of the bundled offering and the commitment to improving access to quality care, this collaboration is poised to make a meaningful impact on public health.
